{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053817","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2026-08-06T11:01:44+00:00","discovered_at":"2026-08-06T11:05:00.260856+00:00","generated_at":"2026-08-06T11:07:16.345063+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Foghorn Therapeutics Q2 2026 net loss narrows to $7.2M; cash runway into H1 2028","bullets":["Net loss of $7.2M vs $17.9M in Q2 2025; collaboration revenue $16.1M (up from $7.6M) due to catch-up adjustment.","Cash, equivalents, and marketable securities $167.6M; runway into first half of 2028.","FHD-909 Phase 1 trial in SMARCA4-mutant NSCLC advancing; combination with anti-PD-1 shows complete tumor regression in preclinical models.","Selective EP300 degrader program targeting IND in 2027 for multiple myeloma and DLBCL; preclinical data outperforms clinical benchmark.","CBPd-171 timeline delayed due to operational issue at third-party CRO; updated guidance pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053817","json":"https://secwatch.observer/filing/0001628280-26-053817.json","markdown":"https://secwatch.observer/filing/0001628280-26-053817.md","text":"https://secwatch.observer/filing/0001628280-26-053817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828026053817/0001628280-26-053817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828026053817/fhtx-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:07:16.345063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}